| Nov 19 |
Novartis ranks first in 2024 Access to Medicine Index
|
| Nov 19 |
Novartis strengthens radiopharma leadership with Ratio Therapeutics deal
|
| Nov 19 |
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
|
| Nov 18 |
Novartis, Ratio to collaborate on SSTR2 radiotherapeutic for cancer
|
| Nov 18 |
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
| Nov 18 |
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
|
| Nov 15 |
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
|
| Nov 15 |
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
|
| Nov 15 |
Ouch: Why a Healthcare Selloff Really Hurts in Europe
|
| Nov 14 |
Down -10.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)
|
